DE69913548D1 - Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen - Google Patents

Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Info

Publication number
DE69913548D1
DE69913548D1 DE69913548T DE69913548T DE69913548D1 DE 69913548 D1 DE69913548 D1 DE 69913548D1 DE 69913548 T DE69913548 T DE 69913548T DE 69913548 T DE69913548 T DE 69913548T DE 69913548 D1 DE69913548 D1 DE 69913548D1
Authority
DE
Germany
Prior art keywords
pain
treatment
anxiety
antagonists
mglur5 antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69913548T
Other languages
English (en)
Other versions
DE69913548T2 (de
Inventor
Hans Allgeier
David Cosford
Josef Flor
Fabrizio Gasparini
Conrad Gentsch
D Hess
Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Andrew Varney
Elebi Goenuel Veli
Katharine Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
SIBIA Neurosciences Inc
Original Assignee
Novartis AG
SIBIA Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69913548(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis AG, SIBIA Neurosciences Inc filed Critical Novartis AG
Application granted granted Critical
Publication of DE69913548D1 publication Critical patent/DE69913548D1/de
Publication of DE69913548T2 publication Critical patent/DE69913548T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DE69913548T 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen Revoked DE69913548T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
GB9821503 1998-10-02
US22081398A 1998-12-23 1998-12-23
US220813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (2)

Publication Number Publication Date
DE69913548D1 true DE69913548D1 (de) 2004-01-22
DE69913548T2 DE69913548T2 (de) 2004-09-23

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69913548T Revoked DE69913548T2 (de) 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Country Status (21)

Country Link
EP (1) EP1117403B1 (de)
JP (1) JP2002526408A (de)
KR (1) KR20010088832A (de)
CN (1) CN1187048C (de)
AT (1) ATE255894T1 (de)
AU (1) AU765644B2 (de)
BR (1) BR9914215A (de)
CA (1) CA2345137A1 (de)
DE (1) DE69913548T2 (de)
DK (1) DK1117403T3 (de)
ES (1) ES2213389T3 (de)
HU (1) HUP0200553A3 (de)
ID (1) ID29095A (de)
IL (2) IL142047A0 (de)
NO (1) NO20011440L (de)
NZ (1) NZ510743A (de)
PL (1) PL202906B1 (de)
PT (1) PT1117403E (de)
RU (1) RU2232017C2 (de)
SK (1) SK4382001A3 (de)
WO (1) WO2000020001A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
ATE297734T1 (de) * 2000-12-22 2005-07-15 Hoffmann La Roche Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2544688B1 (de) 2010-03-02 2016-09-07 President and Fellows of Harvard College Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
JP6603334B2 (ja) 2015-06-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー エチニル誘導体
CN110958879A (zh) 2017-07-31 2020-04-03 诺华股份有限公司 玛沃谷兰在减少可卡因使用或预防复用可卡因中的用途
EP3459939A1 (de) 2017-09-26 2019-03-27 Pragma Therapeutics Neuartige heterocyclische verbindungen als mglur7 modulatoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
WO2000020001A1 (en) 2000-04-13
SK4382001A3 (en) 2001-08-06
HUP0200553A2 (hu) 2002-07-29
ATE255894T1 (de) 2003-12-15
NO20011440L (no) 2001-05-15
BR9914215A (pt) 2001-07-03
IL142047A0 (en) 2002-03-10
CN1187048C (zh) 2005-02-02
NO20011440D0 (no) 2001-03-21
ID29095A (id) 2001-07-26
IL142047A (en) 2007-09-20
PT1117403E (pt) 2004-04-30
NZ510743A (en) 2003-10-31
HUP0200553A3 (en) 2002-11-28
EP1117403B1 (de) 2003-12-10
CN1321087A (zh) 2001-11-07
EP1117403A1 (de) 2001-07-25
DE69913548T2 (de) 2004-09-23
KR20010088832A (ko) 2001-09-28
CA2345137A1 (en) 2000-04-13
ES2213389T3 (es) 2004-08-16
RU2232017C2 (ru) 2004-07-10
PL202906B1 (pl) 2009-08-31
AU6198499A (en) 2000-04-26
JP2002526408A (ja) 2002-08-20
DK1117403T3 (da) 2004-04-13
AU765644B2 (en) 2003-09-25
PL346876A1 (en) 2002-03-11

Similar Documents

Publication Publication Date Title
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60141230D1 (de) Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
DE60233040D1 (de) Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8331 Complete revocation